|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Tumor Biology |
Departments of Pathology (G.G.G., L.E.G., C.A.K.), Immunology (S.B.R., A.Z., C.A.K.), and Physiology (A.Z.), University of Colorado Health Sciences Center, Denver, CO 80262, and The Wistar Institute (D.S.), Philadelphia, PA 19104; USA
2 Address correspondence to Carol A. Kruse, Department of Immunology, Campus Box B216, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262 (carol.kruse{at}uchsc.edu).
Abstract
TALL-104 is a human leukemic T cell line that expresses markers characteristic of both cytotoxic T lymphocytes and natural killer cells. TALL-104 cells are potent tumor killers, and the use of lethally irradiated TALL-104 as cellular therapy for a variety of tumors has been explored. We investigated the interactions of TALL-104 cells with human brain tumor cells. TALL-104 cells mediated increased lysis of a panel of brain tumor cells at low effector-to-target ratios over time. We obtained evidence that TALL-104 cells injured glioma cells by both apoptotic and necrotic pathways. A 7-amino actinomycin D flow cytometry assay revealed that the percentages of both apoptotic and necrotic glioma cells increased after TALL-104 cell/glioma cell coincubations. Fluorescent microscopy studies and a quantitative morphologic assay confirmed that TALL-104 cell/glioma cell interactions resulted in tumor cell apoptosis. Cytokines are secreted when TALL-104 cells are coincubated with brain tumor cells; however, morphologic analysis assays revealed that the soluble factors contained within clarified supernates obtained from 4 h coincubates added back to brain tumor cell cultures did not trigger the glioma apoptosis. TALL-104 cells do not express Fas ligand, even upon coincubation with glioma targets, which suggests that the Fas/Fas ligand apoptotic pathway is not likely responsible for the cell injury observed. We obtained evidence that cell injury is calcium dependent and that lytic granule exocytosis is triggered by contact of TALL-104 cells with human glioma cells, suggesting that this pathway mediates glioma cell apoptosis and necrosis.
References
Barry, M., Heibein, J.A., Pinkoski, M.J., Lee, S.-F., Moyer, R.W.,
Green, D.R., and Bleackley, R.C. (2000) Granzyme B short-circuits
the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte
killing by directly cleaving Bid. Mol. Cell. Biol.
20,3781
-3794.
Berke, G. (1994) The binding and lysis of target cells by cytotoxic lymphocytes: Molecular and cellular aspects. Annu. Rev. Immunol. 12,735 -773.[CrossRef][ISI][Medline]
Bossi, G., and Griffiths, G.M. (1999) Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat. Med. 5, 90-96.[CrossRef][ISI][Medline]
Cappello, P., Novelli, F., Forni, G., and Giovarelli, M. (2002) Death receptor ligands in tumors. J. Immunother. 25,1 -15.
Cesano, A., and Santoli, D. (1992) Two unique human leukemic T-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity analysis and modulation of their lytic mechanisms. In Vitro Cell. Dev. Biol. 28A,648 -656.[CrossRef]
Cesano, A., Visonneau, S., Cioe, L., Clark, S.C., Rovera, G., and Santoli, D. (1994) Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J. Clin. Invest. 94,1076 -1084.
Cesano, A., Visonneau, S., and Santoli, D. (1995)
Treatment of experimental glioblastoma with a human major histocompatibility
complex nonrestricted cytotoxic T cell line. Cancer
Res. 55,96
-101.
Cesano, A., Visonneau, S., Jeglum, K.A., Owen, J., Wilkinson, K.,
Carner, K., Reese, L., and Santoli, D. (1996a) Phase I clinical
trial with a human major histocompatibility complex nonrestricted cytotoxic
T-cell line (TALL-104) in dogs with advanced tumors. Cancer
Res. 56,3021
-3029.
Cesano, A., Visonneau, S., Pasquini, S., Rovera, G., and Santoli,
D. (1996b) Antitumor efficacy of a human major histocompatibility
complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice
bearing syngeneic leukemia. Cancer Res.
56,4444
-4452.
Cesano, A., Visonneau, S., Wolfe, J.H., Jeglum, K.A., Fernandez, J., Gillio, A., O'Reilly, R.J., and Santoli, D. (1997) Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104. Cancer Immunol. Immunother. 44,125 -136.[CrossRef][ISI][Medline]
Chong, A.S., Aleksijevic, A., Scuderi, P., Hersh, E.M., and Grimes, W.J. (1989) Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets. Cancer Immunol. Immunother. 29,270 -278.[ISI][Medline]
Esoterix (2002) Final Report, Serum Dexamethasone. Calabasas Hills, Calif.: Esoterix, Inc., 2002.
Fleshner, M., Watkins, L.R., Redd, J.M., Kruse, C.A., and Bellgrau, D. (1992) A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats. Cell Transplant. 1,307 -312.[Medline]
Freeman, J.E., Winston, K.R., Foreman, N., Paul, D.B., Gup, C.J., Gomez, G., Visonneau, S., Santoli, D., and Kruse, C.A. (1999) Cellular immunotherapy of brain tumors involving intratumoral placements of the irradiated TALL-104 cytotoxic T cell line. Proceedings of the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Pediatric Neurological Surgery 28th Annual Meeting, Atlanta, Ga., pp. 100-101 (abstract).
Geoerger, B., Tang, C.-B., Cesano, A., Visonneau, S., Marwaha, S., Judy, K.D., Sutton, L.N., Santoli, D., and Phillips, P.C. (2000) Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts. Neuro-oncol. 2, 103-113.[Abstract]
Geske, F.J., and Gerschenson, L.E. (2001) The biology of apoptosis. Human Pathol. 32,1029 -1038.[CrossRef][ISI][Medline]
Hehner, S.P., Hofmann, T.G., Ratter, F., Dumont, A., Dröge,
W., and Schmitz, M.L. (1998) Tumor necrosis
factor-
-induced cell killing and activation of transcription factor
NF-
B are uncoupled in L929 cells. J. Biol.
Chem. 273,18117
-18121.
Henkart, P.A., Millard, P.J., Reynolds, C.W., and Henkart, M.P.
(1984) Cytolytic activity of purified cytoplasmic granules from
cytotoxic rat large granular lymphocyte tumors. J. Exp.
Med. 160,75
-93.
Henkart, P.A. (1994) Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules. Immunity 1, 343-346.[CrossRef][ISI][Medline]
Kleinschmidt-DeMasters, B.K., Orr, E.A., Savelieva, E., Owens,
G.C., and Kruse, C.A. (1999) Paucity of retinoic acid receptor
alpha (RAR) nuclear immunostaining in gliomas and inability of retinoic
acid to influence neural cell adhesion molecule (NCAM) expression.
J. Neurooncol. 41,31
-42.[CrossRef][Medline]
Kruse, C.A., and Beck, L.T. (1997) Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours. Biotechnol. Appl. Biochem. 25,197 -205.
Kruse, C.A., and Merchant, R.E. (1997) Cellular therapy of brain tumors: Clinical trials. In Kornblith, P.L., and Walker, M.D. (Eds.), Advances in Neuro-Oncology, II. Armonk, N.Y.: Futura Publishing Company, pp. 487-504.
Kruse, C.A., and Rubinstein, D. (2001) Cytotoxic T-lymphocytes reactive to patient major histocompatibility complex proteins for therapy of brain tumors. In Liau, L.M., Becker, D.P., Cloughesy, T.F., and Bigner, D.D. (Eds.), Brain Tumor Immunotherapy. Totowa, N.J.: Humana Press, pp. 149-170.
Kruse, C.A., Mitchell, D.H., Lillehei, K.O., Johnson, S.D., McCleary, E.L., Moore, G.E., Waldrop, S., and Mierau, G.W. (1989) Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro. Cancer 64,1629 -1637.[CrossRef][ISI][Medline]
Kruse, C.A., Lillehei, K.O., Mitchell, D.H.,
Kleinschmidt-DeMasters, B., and Bellgrau, D. (1990) Analysis of
interleukin 2 and various effector cell populations in adoptive immunotherapy
of 9L rat gliosarcoma: Allogeneic cytotoxic T lymphocytes prevent tumor take.
Proc. Natl. Acad. Sci. USA
87,9577
-9581.
Kruse, C.A., Mitchell, D.H., Kleinschmidt-DeMasters, B.K., Franklin, W.A., Morse, H.G., Spector, E.B., and Lillehei, K.O. (1992) Characterization of a continuous human glioma cell line DBTRG-05MG: Growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In Vitro Cell. Dev. Biol. 28A,609 -614.
Kruse, C.A., Schiltz, P.M., Bellgrau, D., Kong, Q., and Kleinschmidt-DeMasters, B.K. (1994) Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: Chronic therapy for primary brain tumors. J. Neurooncol. 19,161 -168.[CrossRef][Medline]
Kruse, C.A., Cepeda, L., Owens, B., Johnson, S.D., Stears, J., and Lillehei, K.O. (1997) Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol. Immunother. 45, 77-87.[CrossRef][ISI][Medline]
Kruse, C.A., Varella-Garcia, M., Kleinschmidt-DeMasters, B.K., Owens, G.C., Spector, E.B., Fakhrai, H., Savelieva, E., and Liang, B.C. (1998) Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell lines. In Vitro Cell. Dev. Biol. Anim. 34,455 -462.[ISI][Medline]
Kruse, C.A., Visonneau, S., Kleinschmidt-DeMasters, B.K., Gup,
C.J., Gomez, G.G., Paul, D.B., and Santoli, D. (2000) The human
leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors
and traffics through brain tissue: Implications for local adoptive
immunotherapy. Cancer Res.
60,5731
-5739.
Laws, E.R., Jr. (1998) Central nervous system tumors: What have we learned and where are we heading? Ca: Cancer J. Clin. 48,322 , 327-329 (editorial).
Lecoeur, H., de Oliveira-Pinto, L.M., and Gougeon, M.L. (2002) Multiparametric flow cytometric analysis of biochemical and functional events associated with apoptosis and oncosis using the 7-aminoactinomycin D assay. J. Immunol. Methods 265, 81-96.[CrossRef][ISI][Medline]
Li, J.H., Rosen, D., Ronen, D., Behrens, C.K., Krammer, P.H.,
Clark, W.R., and Berke, G. (1998) The regulation of CD95 ligand
expression and function in CTL. J. Immunol.
161,3943
-3949.
Lyubchenko, T.A., Wurth, G.A., and Zweifach, A. (2001) Role of calcium influx in cytotoxic T lymphocyte lytic granule exocytosis during target cell killing. Immunity 15,847 -859.[CrossRef][ISI][Medline]
O'Connor, R., Cesano, A., Lange, B., Finan, J., Nowell, P.C.,
Clark, S.C., Raimondi, S.C., Rovera, G., and Santoli, D. (1991)
Growth factor requirements of childhood acute T-lymphoblastic leukemia:
Correlation between presence of chromosomal abnormalities and ability to grow
permanently in vitro. Blood
77,1534
-1545.
Paul, D.B., and Kruse, C.A. (2001) Immunologic approaches to therapy for brain tumors. Curr. Neurol. Neurosci. Rep. 1,238 -244.[Medline]
Philpott, N.J., Turner, A.J., Scopes, J., Westby, M., Marsh, J.C.,
Gordon-Smith, E.C., Dalgleish, A.G., and Gibson, F.M. (1996) The
use of 7-amino actinomycin D in identifying apoptosis: Simplicity of use and
broad spectrum of application compared with other techniques.
Blood 87,2244
-2251.
Prados, M.D., Berger, M.S., and Wilson, C.B. (1998) Primary central nervous system tumors: Advances in knowledge and treatment. Ca: Cancer J. Clin. 48,331 -360.[Abstract]
Read, S.B., Kulprathipanja, N.V., Gomez, G.G., Paul, D.B., Winston,
K.R., Robbins, J.M., and Kruse, C.A. (2003) Human alloreactive
CTL interactions with gliomas and with those having upregulated HLA expression
from exogenous IFN-
or IFN- gene modification. J.
Interferon Cytokine Res. 23,379
-393.[CrossRef][ISI][Medline]
Redd, J.M., Lagarde, A.C., Kruse, C.A., and Bellgrau, D. (1992) Allogeneic tumor-specific cytotoxic T lymphocytes. Cancer Immunol. Immunother. 34,349 -354.[CrossRef][ISI][Medline]
Saris, S.C., Patronas, N.J., Rosenberg, S.A., Alexander, J.T., Frank, J., Schwartzentruber, D.J., Rubin, J.T., Barba, D., and Oldfield, E.H. (1989) The effect of intravenous interleukin-2 on brain water content. J. Neurosurg. 71,169 -174.[ISI][Medline]
Schmid, I., Uittenbogaart, C.H., Keld, B., and Giorgi, J.V. (1994) A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J. Immunol. Methods 170,145 -157.[CrossRef][ISI][Medline]
Takayama, H., and Sitkovsky, M.V. (1987) Antigen
receptor-regulated exocytosis in cytotoxic T lymphocytes. J. Exp.
Med. 166,725
-743.
Uellner, R., Zvelebil, M.J., Hopkins, J., Jones, J., MacDougall, L.K., Morgan, B.P., Podack, E., Waterfield, M.D., and Griffiths, G.M. (1997) Perforin is activated by a protolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain, EMBO J. 16,7287 -7296.[CrossRef][ISI][Medline]
Vignaux, F., Vivier, E., Malissen, B., Depraetere, V., Nagata, S.,
and Golstein, P. (1995) TCR/CD3 coupling to Fas-based
cytotoxicity. J. Exp. Med.
181,781
-786.
Virasch, N., and Kruse, C.A. (2001) Strategies using the immune system for therapy of brain tumors. Hematol. Oncol. Clinics North Am. 15,1053 -1071.[CrossRef][ISI][Medline]
Visonneau, S., Cesano, A., Tran, T., Jeglum, K.A., and Santoli, D. (1997) Suc cessful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104. Clin. Cancer Res. 3,1789 -1797.[Abstract]
Visonneau, S., Cesano, A., Jeglum, K.A., and Santoli, D.
(1999a) Adjuvant treatment of canine osteosarcoma with the human
cytotoxic T-cell line TALL-104. Clin. Cancer Res.
5,1868
-1875.
Visonneau, S., Cesano, A., Jeglum, K.A., and Santoli, D. (1999b) Adoptive therapy of canine metastatic mammary carcinoma with the human MHC non-restricted cytotoxic T-cell line TALL-104. Oncol. Rep. 6,1181 -1188.[ISI][Medline]
Visonneau, S., Cesano, A., Porter, D.L., Luger, S.L., Schuchter,
L., Kamoun, M., Torosian, M.H., Duffy, K., Sickles, C., Stadtmauer, E.A., and
Santoli, D. (2000) Phase I trial of TALL-104 cells in patients
with refractory metastatic breast cancer. Clin. Cancer
Res. 6,1744
-1754.
Waterhouse, N.J., and Trapani, J.A. (2002). CTL: Caspases terminate life, but that's not the whole story. Tissue Antigens 59,175 -183.[CrossRef][ISI][Medline]
Winer, B.J. (1971) Multifactor experiments having repeated measures on the same elements. In Statistical Principles in Experimental Design, 2nd ed., Chapter 7. New York: McGraw-Hill, pp. 514-603.
Zweifach, A. (2000) Target-cell contact activates a
highly selective capacitative calcium entry pathway in cytotoxic T
lymphocytes. J. Cell Biol.
148,603
-614.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
